Live Attenuated Influenza Vaccine

Phase 3

Live Attenuated Influenza Vaccine is one of 2 therapeutic programs targeting Impact of Vaccination. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Impact of VaccinationNot yet recruiting

Impact of VaccinationPhase 3

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Impact of Vaccination

#DrugCompanyPhaseTrials

Live Attenuated Zoster Vaccine

CChangchun BCHT Biotechnology Co.

Phase 3

1 2

Live Attenuated Influenza Vaccine

UUniversity of Maryland, Baltimore

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

ApprovedNot yet recruiting

Impact of Vaccination

NCT07093281

Clinical

Trials by Indication[1]

Impact of Vaccination1 trial

The Impact of Live Attenuated Intranasal Influenza Vaccine Exposure on Mucosal Immunity

Not yet recruiting·UUniversity of Maryland, Baltimore·Approved·NCT07093281·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Live Attenuated Influenza Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Live Attenuated Influenza Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversity of Maryland, Baltimore

Live Attenuated Influenza Vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Impact of Vaccination1 trial

References

Drug Info

Quick Facts

Related News